Asia
According to the CDC, the Delta variant now accounts for more than 6% of infections in the U.S. and may be responsible for 18% of cases in some Western states.
The Pennsylvania-based eye disease company had to change its application from an Emergency Use Authorization to a full BLA approval.
This week, multiple companies have partnered in attempts to bring forth new therapies. BioSpace takes a look at some of these announcements.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Bharat will conduct Phase IV studies to check real-world efficacy against the virus, while Ocugen says Covaxin will be a valuable tool in helping to end the COVID-19 pandemic.
Not everyone is so confident that Aduhelm will transform the Alzheimer’s drug development landscape.
The first human case of H10N3 avian flu was diagnosed in China in late May. Chinese health authorities claim a low risk of contagion. Learn more about it here.
Shares of Fate climbed nearly 4% in premarket trading after it announced positive interim data from a Phase I study of FT516 for patients with relapsed / refractory B-cell lymphoma.
While several countries rely on Sinovac Biotech to end the pandemic, concerns regarding the shot’s efficacy continue to shroud the vaccine. Currently, it is the second most used vaccine worldwide.
Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers.
PRESS RELEASES